Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Univ. Spin-Off Developing Non-Toxic Bedbug Killer

Research from a lab at Pennsylvania State University led to a technology for controlling bedbug infestations with natural enemies that are harmless to humans. . . . → Read More: Univ. Spin-Off Developing Non-Toxic Bedbug Killer

Medical Robotics Company Crowdfunding IPO

A medical robotics company spun-off from labs at MIT is issuing its initial public stock offering through equity crowdfunding, aiming to raise $15 million. . . . → Read More: Medical Robotics Company Crowdfunding IPO

Allergan to Option Gene Editing for Eye Diseases

International drug maker Allergan is gaining access to treatments for inherited eye diseases being developed by Editas Medicine, a spin-off enterprise from MIT and Harvard. . . . → Read More: Allergan to Option Gene Editing for Eye Diseases

Process Converts Food Waste to Auto Tire Materials

Agricultural scientists in Ohio are developing a process for converting common food waste into materials used in car tires, and filed a patent for these techniques. . . . → Read More: Process Converts Food Waste to Auto Tire Materials

Duchenne Gene-Editing Company Launched, Raising $5M

A biotechnology start-up is applying a process for editing-out disease-causing mutations to correct the inherited disorder Duchenne muscular dystrophy. . . . → Read More: Duchenne Gene-Editing Company Launched, Raising $5M

Patent Issued for Peptides in Diabetes Gene Therapy

A U.S. patent was issued today for synthetic peptides that support gene therapies developed to treat type 2 diabetes and heart failure. . . . → Read More: Patent Issued for Peptides in Diabetes Gene Therapy

Patent Office Decides for Broad and Editas in Crispr Case

The U.S. Patent and Trademark Office decided that the gene editing processes developed by Broad Institute and licensed to Editas Medicine do not interfere with techniques for genome editing created by University of California at Berkeley. . . . → Read More: Patent Office Decides for Broad and Editas in Crispr Case

Tissue Regeneration Start-Up Gains $33M in Early Funds

A new enterprise founded by researchers at Stanford University aims to discover and develop drugs that repair and regenerate tissue from stem cells. . . . → Read More: Tissue Regeneration Start-Up Gains $33M in Early Funds

Biotechs License Solid Tumor Therapy in $2.1B Deal

Biotechnology enterprise Immunomedics Inc. is licensing its enhanced antibody-based treatment for solid tumor cancers to Seattle Genetics, a developer of similar cancer drugs. . . . → Read More: Biotechs License Solid Tumor Therapy in $2.1B Deal

Trial Testing Artificial Pancreas for Type 1 Diabetes

A clinical trial testing day-to-day use of a smartphone-controlled artificial pancreas for people with type 1 diabetes began enrolling participants. . . . → Read More: Trial Testing Artificial Pancreas for Type 1 Diabetes